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Abstract 
Cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) are keratinocyte 
carcinomas (KC), the most frequently diagnosed cancers in fair-skinned populations. Ultraviolet 
radiation (UVR) is the main driving carcinogen for these tumors but immunosuppression, 
pigmentary factors, and aging are also risk factors. Scientific discoveries have improved the 
understanding of the role of human papillomaviruses (HPV) in cSCC as well as the skin 
microbiome and a compromised immune system in the development of both cSCC and BCC.  
Genomic analyses have uncovered genetic risk variants, high-risk susceptibility genes, and 
somatic events that underlie common pathways important in KC tumorigenesis and tumor 
characteristics which have enabled development of prediction models for early identification of 
high-risk individuals.  Advances in chemoprevention in high-risk individuals and progress in 
targeted and immune-based treatment approaches have the potential to decrease the morbidity 
and mortality associated with these tumors.  As the incidence and prevalence of KC continue to 
increase, strategies for prevention, including effective sun protective behavior, educational 
interventions and reduction of tanning bed access and usage are essential. Gaps in our knowledge 
requiring additional research in order to reduce the high morbidity and costs associated with KC 
include better understanding of factors leading to more aggressive tumors, the roles of 
microbiome and HPV infection, prediction of response to therapies including immune 
checkpoint blockade, and how to tailor both prevention and treatment to individual risk factors 
and needs.  
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Introduction 
Keratinocyte carcinoma (KC), comprised of cutaneous squamous cell carcinoma (cSCC) and 
basal cell carcinoma (BCC), are the most frequently diagnosed cancers in the Western world 
(1,2).  Although the exact worldwide incidence of KC is unknown, KC represents a significant 
health burden in many countries. An estimated 5.4 million KC were diagnosed in the United 
States (US) in 2012, an increase from 3.5 million cases in 2006 (3,4). In addition to significant 
morbidity, they are responsible for an estimated 4000-8700 deaths per year in the US and cost 
~$4.8 billion annually (5,6). In 2014 the US Surgeon General launched the “Call to Action to 
Prevent Skin Cancer” which aimed to reduce skin cancer incidence and mortality, including that 
of both KCs and melanoma. Similar campaigns have been launched elsewhere, with most 
notable impact in Australia (7).   
 
Molecular, epidemiological and clinical studies have led to greater understanding of the cellular 
events that occur during tumorigenesis, epidemiological risk factors, and have provided new 
strategies for treatment and prevention of KCs. In this review, we will discuss similarities and 
differences between BCC and cSCC in terms of histopathology, risk factors, and tumor 
development. We also highlight advances and gaps in our knowledge and emerging therapeutic 
and preventative strategies needed to decrease the impact of these cancers. 
 
Overview 
cSCC comprise about 20% of KC diagnoses. An estimated 3-7% of patients develop metastasis, 
of whom more than 70% will die from disease (8-10). BCC comprise about 80% of all KC. 
Despite population studies indicating that the BCC-associated mortality rate is negligible (10), 
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BCC can in rare cases metastasize and lead to death (11). While ratios of BCC to cSCC ranging 
from 2-4:1 have been reported, recent studies based on Medicare records suggest this may be 
changing, with equal numbers of BCCs and cSCCs being treated (3). This may reflect the aging 
of the population. 
 
Risk Factors  
Risk factors for KC and aggressive KC are summarized in Figure 1 and Table 1 and are detailed 
below. Prospective identification of high-risk patients and early intervention are facilitated by 
recognition of specific clinical and histopathologic characteristics for both BCC (12-17) and 
cSCC (9,13,18-22), so that tailored management strategies may be implemented early.  
 
Pathophysiology 
UV radiation 
UV radiation is the overwhelming causative environmental carcinogen in KC. KC exhibit C>T 
or CC>TT dinucleotide mutations at pyrimidine bases with a strong transcription strand bias.  
This mutational signature (Signature 7) is characteristic of UV-induced mutation and common to 
almost all UV-associated skin cancers (23). KC also show a high mutational burden, far 
exceeding that of other cancers, although the genes mutated vary between BCCs and cSCCs 
(24,25). Exome sequencing of cSCC shows highest levels of TP53 mutations and loss of function 
CDKN2A mutations. Other frequent mutations are found epigenetic regulators such as KMT2C, 
KMT2D, TET2, and loss of function Notch pathway genes such as NOTCH1 and NOTCH2 
(24,25). Sequencing studies of metastatic cSCCs reveal higher mutational burden than primary 
tumors and have associated mutations in KMT2C with poorer outcome, including bone 
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metastases (25,26). Targeted sequencing revealed a high proportion of cSCCs (88%) contain 
potentially actionable but rare (<10%) genomic alterations including PIK3CA, FGFR3, BRAF, 
and EGFR, suggesting potential areas for clinical trials (27). Commonly mutated genes in BCC 
include those in the sonic hedgehog (SHH) signaling pathway (PTCH1, SUFU, SMO) as well as 
TP53. Genes mutated less frequently (8-30%) include MYCN, PPP6C, PTPN14, and RB1 (28).   
 
Immunosuppression 
Innate or acquired immunosuppression is a significant risk factor for KC, particularly cSCC. 
Whilst certain primary immunodeficiencies predispose to KC (29) (e.g. severe combined 
immunodeficiency, Wiskott-Aldrich syndrome and dyskeratosis congenita), KC are more 
common in acquired immunodeficiency, including immunosuppressive drug therapy (e.g. in 
solid‐organ transplantation), immune‐mediated/autoimmune inflammatory diseases (IMIDs) 
such as inflammatory bowel disease (IBD), vasculitis and rheumatoid arthritis (RA), non‐
Hodgkin lymphoma/chronic lymphocytic leukaemia (NHL/CLL) and HIV infection (30). 
Solid organ transplant recipients (SOTR) are the most intensively studied iatrogenically 
immunosuppressed population: they have a 60-200 fold increased risk of cSCC, with reversal of 
the usual BCC to cSCC ratio, frequent occurrence of multiple tumors and a potentially more 
aggressive clinical course (31-34). Age-adjusted population estimates in the US have shown 
cSCC incidence ratios (IR) of 1355/100,000 person-years in SOTRs compared with 38/100,000 
in the general population (35). Indeed, KC in SOTR has an IR nearly five times that of all other 
cancers combined in the general US population (National Cancer Institute. 
http://seer.cancer.gov/statfacts/). Significant risk factors include age at transplantation, duration 
of immune suppression, skin type, gender and organ-specific factors, with greatest KC risk seen 
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after thoracic transplantation. In IMIDs the risk of KC is also significantly increased and this is 
in part treatment-related (36):  exposure to thiopurines is associated with up to 5-fold increased 
risk for cSCC in IBD (36,37) and treatment for more than one year also increases cSCC risk in 
RA (38). Other non-iatrogenically immunosuppressed individuals, including those with 
HIV/AIDS or with hematological malignancies such as CLL, are also at significantly increased 
KC risk (39-41). In HIV, this risk is associated with long-term survival although highly active 
antiretroviral therapy may be protective (42). cSCC in association with CLL has poorer 
outcomes with increased recurrence and metastasis (41,43). 
The pathogenesis of immunosuppression-associated KC involves a complex interplay between 
UVR and a number of cofactors. Innate primary and acquired immunodeficiencies are likely to 
result in dysregulation of tumor immune surveillance, as do immune suppressive drugs, but the 
latter may also contribute by direct carcinogenic effects. For example, a recent meta-analysis of 
27 studies confirmed a 1.56-fold increased risk for cSCC (95% CI 1.11-2.18) in association with 
azathioprine (44). Thiopurines have the dual effects of causing UVA photosensitivity with 
consequent UVA-induced DNA damage, together with increased UVB-mutagenesis through 
reduced repair of UVB-induced DNA damage (45,46). A specific azathioprine signature 
mutation has recently been identified in cSCC (47); procarcinogenic mechanisms for the 
calcineurin inhibitor, cyclosporine, include reduced UV DNA damage repair (48), reduced 
apoptotic response to UV (49) and ATF3 induction and suppression of p53-dependent  
senescence (48,50). In contrast, mTOR inhibitors are associated with reduced cSCC risk, 
possibly through both anti-proliferative and anti-angiogenic properties (34,51-53) and the risk 
associated with newer immunosuppressive drugs, including tacrolimus and mycophenolate, may 
also be reduced, but supportive epidemiological data are not yet established (54,55). 
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Voriconazole, an antifungal agent commonly used in transplantation, has direct 
photocarcinogenic effects (56) and is associated with significantly increased risk of aggressive 
cSCC (57).  Other drugs used in IMIDs, including anti-tumor necrosis factor agents, have also 
been implicated in contributing to KC risk, but data are less conclusive.  
 
Human Papillomavirus 
Patients with epidermodysplasia verruciformis (EV), a rare, autosomal recessive disorder 
characterized by impaired cellular immunity, represent another unique population with markedly 
elevated cSCC risk. Cutaneous human papillomavirus virus (cuHPV) of the genus beta (HPV) 
are particularly implicated in cSCC and were first identified in patients with EV, although are 
also common in immunocompetent individuals (58). HPV DNA has been detected in 18-84% 
of cSCCs and is three times more likely to be present in cSCCs arising among 
immunocompromised individuals than immunocompetent individuals (59). However, when 
HPV is detected in cSCC, viral DNA is present at low copy numbers (60), and viral transcripts 
are absent (61).  Therefore, unlike the high-risk mucosal types associated with cervical and 
anogenital cancers, if HPV plays a role in keratinocyte carcinogenesis, it does so through an 
indirect mechanism, such as inhibition of DNA repair and/or apoptosis of UV-damaged cells 
(62).  Multiple epidemiologic studies, incorporating both serologic and DNA-based markers of 
HPV infection, have observed increased risk of cSCC associated HPV infection (63). While 
these associations may simply reflect alterations in immune function that predispose individuals 
to both HPV infection and cSCC, the consistent signal observed across studies underscores the 
need for additional research into the biology underpinning the complex interplay between UV 
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radiation exposure, immune function, HPV infection and KC carcinogenesis, as HPV 
vaccination could be a novel strategy for KC prevention. 
 
Microbiome/Infection  
Chronic skin diseases with altered skin microbiota such as atopic dermatitis (64), psoriasis, and 
hidradenitis suppurativa (65,66) may alter KC development. One study identified 6-N-
hydroxyaminopurine in a strain of S. epidermidis, which can inhibit DNA polymerase in several 
human tumor cell lines, including those derived from cSCC (67). Furthermore, metagenomic 
analyses of the human skin microbiome revealed higher prevalence of such S. epidermis strains 
in healthy individuals. As evidence is currently circumstantial, additional studies are needed to 
further explore the etiopathogenic role of the microbiome in cSCC. 
 
Germline Genetic Risk Factors and Risk Models 
Although factors including immunosuppression, age, sex, pigment, and UV exposure play 
critical roles in the risk of developing KC (Figure 1), highly-penetrant pathogenic variants and 
lower penetrance susceptibility variants also increase risk. Hereditary syndromes associated with 
increased risk of cSCC are rare; these include xeroderma pigmentosa (XP), epidermolysis 
bullosa, Fanconi anemia, oculocutaneous albinism, and aging syndromes such as Werner 
syndrome (reviewed in https://www.cancer.gov/types/skin/hp/skin-genetics-pdq). Basal cell 
nevus syndrome (BCNS/Gorlin Syndrome), caused by pathogenic variants in the PTCH1 gene 
and more rarely PTCH2 (68) and SUFU (69), is the main syndrome associated with an increased 
risk of BCC.  Other syndromes such as Rombo, Bazex-Dupré-Christol, and XP also show 
increased BCC risk (70).  
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Genome-wide association studies (GWAS) have identified variants (or genes) associated with 
increased risk for KC and melanoma. Pathways linked to increased risk of cSCC and/or BCC in 
the general population include genes critical for pigment (IRF4, OCA2, HERC2, TYR, SLC45A2, 
ASIP, RALY, and MC1R), and HLA (HLADQA1) (71,72). BCC GWAS have also identified 
variants in telomere function genes and those important in immune regulation (72).  Most of 
these variants show small effect sizes with typical odds ratios ranging from 1.15 to 1.5. Although 
the total number of variants associated with KC risk is still small, there may be future benefit of 
using polygenic risk scores to identify individuals at elevated risk who would then be candidates 
for sun-protective education, behavioral intervention, and/or increased screening (73,74).   
 
Associations between aberrant human leukocyte antigen (HLA) expression (75,76), or germline 
class-I and II allelic variations and KC have been controversial (77-80) and are affected by high 
UV exposure (81), immunosuppression (82), and HPV infection (83). Multiple variants in HLA-
DRB1 (*01,*07) have shown increased risk for BCC while HLA-DRB1*04 was protective (82). 
HLA-DRB1*01 also correlated with increased BCC risk and early tumor development in renal 
transplant recipients (84). Among immunosuppressed patients, class-I antigens HLA-A03, HLA-
A11 and HLA-B27 and class-II antigens, HLA-DRB1*07 and HLA-DQA1*01 correlated with 
increased risk cSCC (80). GWAS analyses revealed higher cSCC risk in association with 
DRB1*01, DQA1*05:01 and DQA1*05:05 (85), in addition to variants in HLA-DQB1 (72), 
HLA-DQA1 (71), HLA-DRB1 (85) and HLA-DQA1 (85). On the other hand, HLA mismatch 
between recipient and graft appears to have a protective effect on KC risk, with greater number 
of mismatched alleles conferring higher protective effect (S. Arron, manuscript under review). 
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Further studies may reveal the connection between HLA Class I and II antigens and KC 
development. 
 
Prevention  
Sun avoidance and sun protective behavior such as avoiding the sun at peak hours between 11am 
and 3pm, wearing protective clothing and wide-brimmed hats, regularly applying sunscreen and 
seeking shade have been shown in some studies to decrease the incidence of cSCC and may be 
effective for reduction of BCC (86,87). However, consistent adherence to these guidelines, even 
in high-risk populations, such as SOTRs, is suboptimal (88,89). Evidence shows that raising skin 
cancer awareness in high-risk populations can stimulate adoption of preventive practices (90,91) 
and that specific sun-protection education in specialist dermatologic-surgery clinics for SOTRs 
at very high KC risk, can bring about measurable behavior change (92). There remains a need for 
new studies to determine the delivery of effective education programs for sustained sun 
protective behavior strategies for prevention of KCs and to develop these to the point of regular 
use. Chemopreventive strategies for high- risk patients is also a consideration. The few clinical 
trials evaluating the effectiveness of preventive agents (e.g. tretinoin, vismodegib, nicotinamide) 
mostly were conducted in immunocompetent populations (93-95). Oral retinoids such as 
isotretinoin and acitretin, and SHH pathway inhibitor vismodegib all showed decreases in the 
number of BCCs in individuals with BCNS compared to placebo (94,96,97). Isotretinoin is 
associated with decreases in both BCCs and cSCCs in individuals with XP and in SOTRs 
(98,99). However, these drugs have limitations which restrict their use in the general population; 
for example, systemic retinoids are associated with hepatotoxicity and teratogenicity as well as 
xerosis, and vismodegib is associated with dysgeusia and alopecia (100). A double-blinded, 
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randomized controlled trial of nicotinamide (vitamin B3) in patients with a history of KCs found 
that 500 mg nicotinamide twice-daily reduced the incidence of BCC, cSCC and actinic keratosis 
compared to placebo over a 12-month period without significant side effects (93). However, 
there is limited evidence available for nicotinamide in OTRs in KC prevention (101), which 
requires confirmation in large clinical trials. 
  
Screening 
Screening the general population for KC via full body skin examination is unlikely to be cost-
effective in unselected populations because specificity and accuracy of clinical diagnosis is low, 
and the US Preventative Service Task Force states that there is insufficient evidence to 
recommend KC screening for the general population (102).  Increased surveillance is likely to 
occur resulting in increased burden on health services and costs, with unclear reduction in 
morbidity or mortality. On the other hand, KC screening in high-risk groups such as SOTRs may 
have has the potential to reduce morbidity and mortality, although there is no clear consensus on 
optimal screening regimens (103).  
Risk models to identify individuals at highest risk for KC include sex and pigmentation, and for 
SOTRs, also include pre-transplant skin cancer history and age at transplant (104). Despite 
similarities, the different models vary in the exact factors included. The three models for SOTRs 
developed in small cohorts of white renal transplant recipients may not be generalizable to other 
populations or organ types (105-107). An ideal risk prediction tool would stratify patients based 
on individual factors and translate to evidence-based screening recommendations (reviewed in 
(104)). Implementation of existing skin cancer screening guidelines has been variable (108-112), 
likely reflecting availability of resources. A recent population-based study in Ontario, Canada 
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observed that fewer than half of SOTRs ever saw a dermatologist, but that higher adherence to 
annual screening after transplantation was associated with a reduction in surgically-morbid or 
fatal KCs (113). Economic modeling also suggests that appropriate screening and early 
intervention may reduce the cost of skin cancer care after transplant (114) but prospective data 
are needed to further justify targeted screening for reduction in KC morbidity and associated 
costs. 
 
Treatment  
Both BCC and cSCC can be successfully treated by a variety of modalities and guidelines for 
their management have been recently published (13,115-117). Treatment selection is often 
guided by patient features, such as co-morbidities and preferences, tumor features, that stratify 
KCs into low-risk and high-risk tumors (Table 1 and Figure 1), as well as care features, such as 
access to the modality and associated cost (118).  
 
Surgery remains the mainstay of treatment for invasive KC and includes excision with post-
operative margin assessment and Mohs micrographic surgery (MMS).  Low-risk primary KCs 
are often treated with surgical excision whereas high-risk KCs are candidates for MMS.  Non-
surgical destructive options include cryosurgery, electrodessication and curettage (EDC), and 
chemical peels. EDC is widely used for low-risk KCs in non-hair bearing areas on the trunk and 
extremities whereas chemical peels can be used to remove superficial KCs and associated sun-
damage. Light based therapies, including photodynamic therapy (PDT) and lasers, utilize 
discrete wavelengths of light to target KCs. Cure rates depends on tumor features, choice of 
photosensitizing agent, and the light source. PDT can be used to treat low-risk superficial tumors 
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in non-hair bearing areas. Radiation therapy is recommended for non-surgical candidates and as 
adjuvant treatment for tumors with extensive perineural involvement but is not recommended for 
patients <60 years of age or those individuals with genetic syndromes predisposing to increasing 
skin cancer risk.  Topical treatment regimens, including 5-fluorouracil, imiquimod, ingenol 
mebutate, diclofenac and tazarotene, are typically reserved for superficial BCCs or SCC in-situ. 
Dosing regimens and cure rates vary and are impacted by the anatomic site of the tumor, side 
effect profiles and patience compliance. Intralesional treatment with methotrexate, 5-
fluorouracil, bleomycin, or interferon is an option for patients with low-risk tumors who are not 
surgical candidates.  
 
For unresectable or metastatic SCC, chemotherapeutic options have included the infusion of 
cisplatin, 5-FU, bleomycin, and interferon–α2a, with low clinical response rates (<30%) 
(118,119). EGFR inhibition with agents including cetuximab, lapatinib, and panitumumab has 
shown a moderate response but their use is limited by adverse events profiles (118,120). Newer 
treatments, including targeted therapy for BCCs and immunotherapy and checkpoint inhibition 
therapy for cSCCs, hold some promise in the treatment of advanced and unresectable KCs. 
Currently available molecular therapies targeting the SHH signaling pathway often mutated in 
BCCs include vismodegib and sonidegib. Both agents have shown clinically meaningful 
response rates with 43% for locally advanced and 30% for metastatic disease (121-123). Their 
clinical utility is, limited by their side effect profile, which includes muscle spasms, alopecia, 
taste loss, weight loss, precluding their long-term use (121-123). Inhibition of DNA repair 
pathways, including PARP inhibition, is a promising future therapeutic direction for SHH 
pathway-resistant BCCs (124). Immune checkpoint blockade has successfully treated 
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hypermutated cancers, including SCC, enabling heightened sensitivity to effector T cells. 
Cemiplimab, a human monoclonal antibody directed against programmed death 1, is an immune 
checkpoint inhibitor that has demonstrated clinical response in locally advanced (50%) and 
metastatic (47%) disease (125). Immune checkpoint blockade combined with other treatment 
modalities is a promising avenue for future systemic SCC treatment. Identification of which 
tumors will respond is an ongoing area of research. Table 2 describes commonly used KC 
treatments and includes recommendations for use of each treatment modality (116,117,119-144).  
Development of novel transdermal delivery systems such as nanoshells, sonophoresis and 
electroporation offer promising non-invasive alternatives for the future. Despite these advances, 
more data are needed to make informed decisions based on individualized risk-assessments 
guided by patient, tumor, and care factors. Appropriate therapeutic choice involves a shared 
decision-making plan that includes the provider and the patient. 
 
Conclusions: 
With increasingly longer life expectancies, the health burden associated with KCs is likely to rise 
still further. Our understanding of environmental risk factors such as exposure to UV radiation, 
immune suppression, viruses, skin microbiome, and intrinsic risk factors such as pigmentation, 
aging, immune function and genetic susceptibility variants on KC development is growing.  
However, additional research is critical in order to build on these findings, specifically to 
enhance sun protective behavior and public knowledge of the long-term harms of excessive UV 
exposure, to decrease the availability and use of indoor tanning, better capture and track KC 
cases via registries, improve therapies and better predict response (Figure 2). 
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Figure Legends: 
Figure 1:  Unique and shared risk factors for BCC and cSCC 
Intrinsic and extrinsic risk factors for the development of BCC and cSCC are shown including 
factors that are in common or unique to each tumor type. 
 
Figure 2:  Areas of Research Need 
Some of the clinical and scientific areas in need of additional research to drive improvements in 
KC understanding, prevention, treatment, and outcomes are highlighted. IS, immunosuppression; 
SOTR, solid organ transplant recipients; RTR, renal transplant recipients. 
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Table 1. Low and high-risk features of keratinocytic carcinomas.  
Features Low-risk High-risk References 
Basal Cell Carcinoma  
Patient Immune status Immunocompetent Immunosuppressed 12, 13 
Clinical Primary vs. 
recurrent* 
Primary Recurrent, metastatic 
13, 14, 15, 
17 
Anatomic location Area L and M Area H  
Site of prior radiation 
therapy* 
No Yes 
 
Tumor dimensions* 
Surface area: Area L: < 
20 mm; Area M: < 10 
mm 
Size/diameter: < 5 cm 
Surface area: Area L: > 20 
mm; Area M: > 10 mm 
Size/diameter: > 5 cm 
 
Tumor 
circumscription* 
Well-defined borders Poorly-defined borders 
 
Involvement of 
named nerves* 
Absent Present 
 
Pathologic Histologic type / 
growth pattern* 
Superficial, nodular, 
keratotic, 
infundibulocystic, 
fibroepithelioma of 
Pinkus 
Micronodular, infiltrative, 
sclerosing, morpheaform, 
basosquamous, 
metatypical/sarcomatoid 
13, 14, 16, 
17 
Perineural invasion* Absent Present,  diameter of involved 
nerve ≥ 0.1 mm, multifocality, 
involvement of named nerves 
 
Squamous Cell Carcinoma  
Patient Immune status* Immunocompetent Immunosuppressed 13, 18, 19, 
21 
Neurologic 
symptoms* 
Absent Present  
Clinical Primary vs. 
recurrent* 
Primary Recurrent, metastatic 9, 13, 18, 
19, 21, 22 
Anatomic location Area L and M Area H  
Site of prior radiation 
therapy* 
No Yes  
Site of chronic 
inflammation* 
No Yes  
19 
 
Rate of growth* Slow Rapid  
Tumor dimensions* Surface area: Area L: < 
20 mm; Area M: < 10 
mm 
Size/diameter: < 2 cm 
Surface area: Area L: > 20 
mm; Area M: > 10 mm 
Size/diameter: > 2 cm 
 
Tumor 
circumscription* 
Well-defined borders Poorly-defined borders  
Involvement of 
named nerves 
Absent Present  
Extension into 
osseous structures 
Absent Present  
Pathologic Histologic grade* Well or moderately 
differentiated (G1-2) 
Poorly differentiated (G3) 9, 13, 18-22 
Histologic type / 
growth pattern* 
Subtype not otherwise 
specified 
Acantholytic (adenoid), 
adenosquamous, desmoplastic, 
spindled, metaplastic/ 
sarcomatoid 
 
Perineural invasion* Absent Present,  diameter of involved 
nerve ≥ 0.1 mm, multifocality, 
involvement of deep dermal 
nerves or named nerves 
 
Lymphovascular 
invasion* 
Absent Present  
Anatomic (Clark) 
level*  
I-III IV-V   
Tumor depth* < 2.0 mm > 2.0 mm  
Lymph node 
metastasis 
Absent Present, size of metastasis > 
3.0 cm, presence of extranidal 
extension, involvement of 
contralateral lymph nodes 
 
* Features defined by the National Comprehensive Cancer Network 
 Human body skin is classified into three regions according to risk for aggressive KC: area H with high-
risk (frontal hair-line, central face, nose, eyelids, chin, ear, genitalia, hands, feet and bald scalp); area M 
with moderate-risk (cheeks, forehead, scalp, neck, jawline); and area L with low-risk (trunk and 
extremities, excluding H and M areas) 
  
20 
 
Table 2: Description, comparison, and efficacy, and recommended target of common KC treatments  
Treatment  Description Advantage(s) Disadvantage(s) Efficacy/ 
Recurrence 
Rate 3  
Recommended 
target 
References 
Surgery 
Excision Standard surgical 
excision followed 
by postoperative 
pathologic 
evaluation of 
margins. 
- Lower cost than 
Mohs 
- Fast healing if 
surgically repaired  
- Allows for 
pathologic 
confirmation of tumor 
removal 
- Normal tissue not 
maximally conserved 
- May lead to substantial 
deformity in some 
anatomic sites (eyelid, 
nose)  
- BCC/SCC 
combined 5-year 
recurrence rate 
of 3.5% (CI: 1.8-
5.2)  
- Low-risk primary 
tumors 
- Select high-risk 
tumors with margin 
assessment  
116, 117, 
126 
Mohs Surgical resection 
with intraoperative 
analysis  
of 100% of the 
excised margins 
- Highest cure rate  
- Normal tissue 
maximally conserved 
- Allows for 
pathologic 
confirmation of tumor 
removal 
- More expensive than 
excision  
- Requires specialist to 
perform 
- BCC/SCC 
combined 5-year 
recurrence rate 
of 2.1% (0.6-
3.5%)  
- High-risk tumors  116, 117, 
126 
Destruction 
ED and C Tumor is scraped 
from the skin and 
electricity is used 
to destroy 
remaining cancer 
cells in the tumor 
bed 
 
- Minimally invasive  
- Cost-effective 
- Worse cosmetic 
outcome (atrophic scar)  
- Slow healing  
- Cannot be used for 
tumors invading fat 
- BCC/SCC 
combined 5-year 
recurrence rate 
of 4.9% (CI: 2.3-
7.4%) 
- recurrence rates 
highly location 
and operator 
dependent 
- Low-risk KCs on 
the trunk and 
extremities (in non-
terminal hair 
bearing areas) 
116, 117, 
126 
Cryotherapy Uses liquid 
nitrogen to 
destroys tumors 
cells by freeze-
thaw cycles, 
reducing the 
temperature of 
- Minimally invasive  
- Cost-effective 
- minimizes injury to 
normal tissue  
- Simple to perform  
- Potentially painful to 
patient  
- Worse cosmetic 
outcomes compared with 
other treatment options 
- BCC: 0-16.5% 
recurrence rate 
- SCC: 0.8% (CI: 
0.1-2.2%) after 
variable follow 
up  
- Low-risk tumors 
when more effective 
therapies are 
contraindicated  
116, 117, 
126-128 
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target tissue to -50 
to -60oC 
Chemical Peels - Topical solution 
that causes 
exfoliation, 
removing 
superficial KCs 
  
- Minimally invasive  - Potential scarring (deep 
peels) 
- long recovery time 
- Can only be used for 
superficial tumors  
- Long term 
efficacy data 
lacking  
- Superficial 
primary tumors  
130 
Light Based Therapies 
PDT  Application of a 
photosensitizing 
agent 
(aminolevulinic 
acid-ALA or 
methyl 
aminolevulinate -
MAL) which 
concentrate 
selectively in 
rapidly dividing 
cells; followed by 
exposure to light 
source, generating 
reactive oxygen 
species that destroy 
actively 
proliferating 
cancer cells 
- Noninvasive  
- Selective 
- May be painful 
- Good cosmetic result  
- Only recommended for 
superficial tumors  
- Treatment often not 
covered by insurance 
carriers 
- Requires specialized 
equipment  
- Requires training to 
perform 
- Can be costly 
 
- BCC w/ MAL: 
5-year 
recurrence rate 
of 30.7% (CI: 
21.5-42.6%) 
- SCCs with 
variable follow-
up: recurrence 
rate of 26.4% 
(CI: 12.3 to 
43.7%) 
 
- Primary superficial 
low-risk tumors  
116,117, 
131, 132 
Lasers - Ablative: use of a 
coherent light to 
ablate skin cancer 
(CO2 laser)  
 -Non-ablative: 
selectively 
converts light to 
heat inside blood 
vessels (pulse dye 
lasers), destroying 
tumor 
- Good cosmetic 
outcome (non-
scarring) 
- Ablative lasers can 
also treat chronic 
photodamaged  skin 
(photorejuvenation) 
 
 -  BCC 
recurrence rate 
after neodymium 
laser treatment: 
3.7% after 3 mo-
5 year follow-up  
- SCC after 
neodymium 
laser treatment: 
recurrence rate 
of 4.4% after 3 
- Resurfacing may 
be of benefit for 
those with multiple 
superficial, primary 
tumors and severe 
actinic damage  
133, 134 
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mo-5 year 
follow-up 
 
Radiation  
Traditional  - SXRT1: uses high 
energy rays such as 
x-rays to destroy 
the KC  
- EBRT2: uses 
particles (photons, 
electrons or 
protons, most 
commonly electron 
beams) to the KC   
- Suitable alternative 
when surgery is 
contraindicated 
- Minimally invasive  
 
- Expensive  
- Must be performed 
with special equipment  
- Requires multiple 
office visits  
- Higher recurrence rate 
than surgery 
- causes DNA damage, 
increasing future KC 
risk 
 
- BCC 5-year 
recurrence rates 
after SXRT: 
4.2% (CI: 1.9-
6.4%)   
- SCC 5-year 
recurrence rates 
after SXRT: 
5.8% (CI: 2.9-
8.7%) 
-SCC recurrence 
rate after EBRT: 
6.4% (CI: 3.0%-
11.0%) 
- Low-risk tumors 
when surgery is not 
feasible or preferred  
- Contraindicated in 
genetic conditions 
predisposing to skin 
cancer (e.g., basal 
cell nevus 
syndrome, 
xeroderma 
pigmentosum)  
- Contraindicated in 
skin cancer patients 
with connective 
tissue diseases (e.g., 
lupus, scleroderma) 
- Not recommended 
for patients age <60 
years 
- Need long-term 
data on 
brachytherapy  
116,117, 
132, 135 
Brachytherapy  Focuses X-ray 
radiation to the 
tumor with the aid 
of a shielded 
surface 
- High dose of 
treatment to target 
tissue  
- Maximal sparing 
normal tissue  
- Shorter treatment 
times  
- Must be performed 
using special equipment  
- Long-term side effects 
include pigmentation 
changes, hair loss, and 
atrophy 
 
- recurrence rate 
varies between 
0-16.7% over a 
period of 9 mo- 
10 years 
136 
 
Topical Treatment  
5-Fluorouracil  Pyrimidine analog 
that disrupts DNA 
synthesis 
 
 
- Minimally invasive  
- Multiple dosing 
regimens  
- Side effects include 
significant local skin 
reactions with erythema, 
erosions, and crust that 
can last longer than a 
month  
Clearance rates 
varied by 
regimen and 
most studies 
lacked long term 
follow up.  
- Superficial 
primary BCCs, not 
currently 
recommended for 
cSCCs based on 
data available  
137 
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- Limited data regarding 
comparative  efficacy  
- Imiquimod used over a 
large surface area can 
cause systemic 
symptoms such as the 
flu, fatigue, headaches, 
and myalgia  
 
Clearance rates 
from systematic 
review:  
-Superficial 
BCC: 90% 
- SCC in situ= 
27-85%  
Imiquimod Stimulates the 
immune system 
through binding to 
toll-like receptor 7 
 
Clearance rates 
varied by 
regimen and 
most studies 
lacked long term 
follow up.  
Clearance rates 
from systematic 
review:  
-Superficial 
BCC: 43-100%  
- Nodular BCC: 
42-100%  
- Infiltrative 
BCC= 56-63%  
- SCC in situ= 
73-88%  
- Invasive SCC= 
71%  
 
137 
Tazarotene Binds to retinoid 
receptors, blocking 
the differentiation 
of keratinocytes 
-BCC: complete 
response rate of 
30.5% after 3 
year follow-up 
- SCCIS: pilot 
study showed 
complete 
response of 
46.6% patients 
after 3-5mo 
follow-up 
138, 139 
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Ingenol 
mebutate 
Protein C 
activation 
- Superficial 
BCC: clearance 
rate of 63% (5/8 
patients) after 85 
d follow-up  
- No large scale 
data published 
on SCCs 
140 
Diclofenac  Cyclooxygenase 
inhibitor 
- Superficial 
BCC:  clearance 
rate of 64.3% 
after 8 weeks of 
therapy 
141 
Intralesional Injection  
Methotrexate, 
5-fluorouracil, 
bleomycin, or 
interferon 
- Injection of agent 
into KC 
- Alternative for 
patients in whom 
surgery is 
contraindicated  
 
- No therapeutic 
guidelines  
- Side effects include 
pain, erythema, 
ulceration; necrosis 
 
- Lack of large 
scale study of 
efficacy  
- From 
systematic 
review: 
Interferon alpha 
2a cure rate: 
BCC= 68% 
(45/66); SCC= 
90% (28/31)  
- Interferon 
alpha 2b cure 
rate: BCC= 76% 
(363/479);  
- Interferon beta 
cure rate: BCC= 
68% (128/202)  
- Fluorouracil 
cure rate: BCC= 
96% (23/24)  
- Bleomycin cure 
rate:  100% 
(11/11)  
 
Consider for use in 
inoperable tumors  
142 
Systemic Therapies  
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Smoothened 
Inhibitors  
Smoothened 
inhibitors 
(vismodegib 
and sonidegib) 
hinder HH 
pathway activation 
 
- Can be used for 
inoperable tumors, 
locoregional or 
metastatic BCC 
- Adverse events: muscle 
spasms, weight loss, 
dysgeusia, alopecia 
raised creatinine kinase 
and lipase (sonidegib),  
- Some BCCs develop 
resistance 
 
- Median 
duration of 
response: 7.6 
months  
- Metastatic 
BCC response 
rate: 30% (CI: 
16-48%) with 
follow-up until  
9 month after 
first treatment of 
last enrolled 
patient 
- Locally 
advanced BCC: 
43% (CI: 31-
56%) with 
follow-up until 9 
months 
Metastatic BCC or 
locally advanced 
BCC, genetic 
syndromes that 
increase BCC risk 
121-123, 
143 
Epidermal 
Growth Factor 
Inhibitors 
- EGFR is 
expressed by >90% 
of SCCs  
EGFR inhibitors 
disrupt key cellular 
processes  
- Agents used in 
cSCC include 
cetuximab, 
lapatinib, and 
panitumumab 
- Can be used for 
inoperable tumors, 
locoregional or 
metastatic cSCC 
- Side effects and 
systemic toxicity 
including acne-like rash 
in 78% of patients, 
infusions reactions, and 
interstitial pneumopathy  
 
-Response rate 
varying from 31- 
69% 
-SCC after 
panitumumab: 
response rate of 
31% with 
median 
progression free 
survival of 8 
months 
-SCC after 
cetuximab: 
response rate of 
69% (CI: 52-
84%) after 6 
weeks treatment 
Metastatic cSCCs 119, 101, 
144 
PD-1 / PD-L1 
inhibitors  
- Immune 
checkpoint 
inhibition that 
allows T cells to 
- Can be used for 
inoperable tumors, 
locoregional or 
metastatic cSCC 
- Side effects: fatigue, 
nausea, constipation, 
rash, diarrhea; pleural 
Metastatic SCC: 
response rate of 
47% (CI: 34-
61%) after 
Locally advanced 
and metastatic 
cSCCs  
125 
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attack cancer cells 
(e.g. nivolumab, 
cemiplimab, 
pembrolizumab) 
 
effusion, hypercalcemia, 
cellulitis, pneumonitis  
 
median follow-
up of 7.9 months 
Not recommended 
for solid organ 
transplant recipients 
1 SXRT: superficial x-ray therapy 
2 EBRT: Electron beam radiation therapy 
3Many of these studies are small, retrospective and/or have potential selection biases so should be interpreted with caution. 
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